Trifirò Gianluca, Parrino Fabrizio, Sultana Janet, Giorgianni Francesco, Ferrajolo Carmen, Bianchini Elisa, Medea Gerardo, Benvenga Salvatore, Cricelli Iacopo, Cricelli Claudio, Lapi Francesco
Department of Clinical and Experimental Medicine, Pharmacology section, University of Messina, Messina, Italy,
Clin Drug Investig. 2015 Mar;35(3):187-95. doi: 10.1007/s40261-015-0271-0.
Several drugs may interact with levothyroxine and reduce its bioavailability. The aim of this study was to analyse the Italian general practice patients with hypothyroidism from 2002-2011, in terms of variation of thyroid-stimulating hormone (TSH) levels, number of levothyroxine prescriptions and dose of levothyroxine before and during potential drug-drug interactions (DDIs).
Data were extracted from the Italian general practice Health Search CSD Longitudinal Patient Database (HSD). Analysis was limited to individuals aged 18 years and older with at least one levothyroxine prescription from 2002 to 2011 and at least one year of clinical history recorded in HSD. A quasi-experimental pre-post analysis was carried out using a self-controlled study design, on an intention-to-treat basis.
Overall, 5,426 levothyroxine users (7.5 % of population in HSD) were included in the study. The incidence rate ratio comparing the TSH trend before and during the period of exposure to potential DDI showed a significant increase of TSH levels during initial exposure to potential DDI, which decreased over time. The number of prescriptions and dose of levothyroxine decreased before the potential DDI and increased symmetrically during the period of exposure to potential DDI.
The co-prescription of levothyroxine and potentially interacting drugs results in an increased use of levothyroxine. Clinicians should carefully consider adjusting levothyroxine therapy in presence of concomitant drugs, such as proton-pump inhibitors, which may reduce levothyroxine bioavailability.
几种药物可能与左甲状腺素相互作用并降低其生物利用度。本研究的目的是分析2002年至2011年期间意大利初级医疗中甲状腺功能减退患者在潜在药物相互作用(DDIs)之前和期间促甲状腺激素(TSH)水平的变化、左甲状腺素处方数量以及左甲状腺素剂量。
数据从意大利初级医疗健康搜索CSD纵向患者数据库(HSD)中提取。分析仅限于2002年至2011年期间年龄在18岁及以上且至少有一张左甲状腺素处方且在HSD中有至少一年临床记录的个体。采用自我对照研究设计,在意向性治疗基础上进行准实验性前后分析。
总体而言,5426名左甲状腺素使用者(占HSD人群的7.5%)被纳入研究。比较潜在DDI暴露期之前和期间TSH趋势的发病率比显示,在初次暴露于潜在DDI期间TSH水平显著升高,随后随时间下降。左甲状腺素的处方数量和剂量在潜在DDI之前减少,在潜在DDI暴露期间对称增加。
左甲状腺素与潜在相互作用药物的联合处方导致左甲状腺素使用增加。临床医生在存在可能降低左甲状腺素生物利用度的伴随药物(如质子泵抑制剂)时,应谨慎考虑调整左甲状腺素治疗方案。